The FDA has approved a new extended-release version of Oxycodone that contains abuse-deterrent properties. The drug, Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), is an extended-release/long-acting opioid to treat severe pain that requires daily treatment.

Targiniq ER has properties that are expected to impede abuse of the drug by snorting and injection. When snorted or injected, the naloxone in Targiniq ER blocks the euphoric effects of oxycodone, making it less appealing to abusers. 

The drug should only be prescribed to people for whom alternative treatment options are ineffective, not tolerated or would be otherwise inadequate to provide sufficient pain management.

The FDA is requiring studies of Targiniq ER, to assess the serious risks of abuse, increased sensitivity to pain, addiction, overdose, and death associated with use beyond 12 weeks.